Vaccitech Revenue 2020-2021 | VACC

Vaccitech revenue from 2020 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Vaccitech Annual Revenue
(Millions of US $)
2020 $5
2019 $7
Vaccitech Quarterly Revenue
(Millions of US $)
2021-06-30 $0
2021-03-31 $0
2020-12-31
2020-06-30 $1
2020-03-31 $1
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.533B $0.005B
Vaccitech plc is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. Vaccitech plc is based in OXFORD, United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29